Bio-Path Holdings, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vikram Paul Grover
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4710 Bellaire Boulevard Bellaire TX United States of America 77401
- IPO Date
- Mar 4, 2008
- CIK
- 0001133818
- Website
- biopathholdings.com
- Similar Companies
- Business
- Bio-Path Holdings, Inc. (BPTH) is a clinical-stage biotechnology company focused on developing RNAi nanoparticle drugs using its proprietary DNAbilize liposomal delivery technology for oncology and metabolic diseases; the platform enables systemic delivery of antisense oligonucleotides via simple intravenous infusion to target cancer cell proteins and pathways. Founded in 2007 and headquartered in Bellaire, Texas, the company operates primarily in the United States with a pipeline addressing high-unmet-need indications including acute myeloid leukemia (AML), lymphoma, solid tumors, and obesity-related Type 2 diabetes; its core product candidates include prexigebersen (BP1001; Liposomal Grb2 Antisense), in Phase 2 trials for front-line and relapsed/refractory AML patients ineligible for intensive chemotherapy; BP1001-A, a modified formulation of prexigebersen in Phase 1/1b trials for advanced solid tumors such as ovarian, endometrial, and pancreatic cancers, and in preclinical development for obesity and metabolic diseases demonstrating restored insulin sensitivity in cell models; BP1002 (Liposomal Bcl-2 Antisense), in Phase 1/1b trials for refractory/relapsed lymphoma, chronic lymphocytic leukemia, and AML including venetoclax-resistant patients, with recent progression to a 90 mg/m2 dose cohort; and BP1003 (Liposomal STAT3 Antisense), advancing toward an investigational new drug application for pancreatic cancer, non-small cell lung cancer, and AML. Recent developments include preclinical data in December 2024 and March 2025 supporting BP1001-A's potential in obesity by attenuating insulin resistance and enhancing sensitivity in muscle and liver cell models, prompting plans for regulatory designations to accelerate development; expanded global intellectual property with new U.S. and New Zealand patents issued in February 2025 covering P-ethoxy nucleic acids for STAT3 inhibition and liposomal formulations, bolstering protection across 26 countries; an equity purchase agreement with Lincoln Park Capital for up to $7 million in funding; and positive clinical updates from the BP1002 Phase 1/1b AML trial showing patient responses.
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)
Critical Analysis: Amarillo Biosciences (OTCMKTS:AMAR) vs. Bio-Path (NASDAQ:BPTH)
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Bio-Path Holdings Provides Clinical and Operational Update
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Bio-Path Holdings Reports Full Year 2024 Financial Results
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Bio-Path Holdings Provides Key Clinical Updates
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Bio-Path Holdings Provides 2025 Clinical and Operational Update
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules